PCM
KYNB

Palisade Capital Management’s Kyntra Bio KYNB Stock Holding History

Palisade Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,904
Closed -$985K – 488
2016
Q3 		$985K Sell
1,904
-556
-23% -$262K 0.04% 415
2016
Q2 		$1.01M Buy
2,460
+246
+11% +$113K 0.04% 413
2016
Q1 		$1.18M Buy
2,214
+131
+6% +$65.3K 0.04% 406
2015
Q4 		$1.59M Sell
2,083
-917
-31% -$609K 0.05% 368
2015
Q3 		$1.64M Buy
3,000
+400
+15% +$242K 0.05% 363
2015
Q2 		$1.53M Buy
2,600
+1,000
+63% +$582K 0.04% 373
2015
Q1 		$1.25M Buy
1,600
+400
+33% +$310K 0.03% 376
2014
Q4 		$820K Buy
+1,200
New +$772K 0.02% 391

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Palisade Capital Management's KYNB Position: Q4 2016 in Review

Palisade Capital Management sold out of Kyntra Bio (KYNB) in Q4 2016, closing a stake of 1,904 shares — an estimated $985K sold.

Palisade Capital Management first reported a position in KYNB in Q4 2014 and held it in 8 quarters. The position peaked at $1.64M in Q3 2015. 140 funds tracked by Wall St. Rank hold KYNB as of Q4 2016.

  • Palisade Capital Management reported no remaining Kyntra Bio position as of Q4 2016 after selling out during the quarter.
  • Palisade Capital Management sold 1,904 Kyntra Bio shares in Q4 2016, an estimated $985K.
  • Palisade Capital Management first reported a position in Kyntra Bio in Q4 2014 and held it in 8 quarters.
  • Palisade Capital Management's Kyntra Bio position peaked at $1.64M in Q3 2015.
  • 140 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.